高频rTMS联合利培酮治疗精神分裂症的临床效果被引量：3

下载PDF

导出

摘要目的探讨高频重复经颅刺激(rTMS)联合利培酮对精神分裂症患者阳性和阴性症状量表(PANSS)评分及生活质量的影响。方法选取河南科技大学第五附属医院74例精神分裂症患者,按照治疗方案分为参照组和研究组,各37例。参照组接受利培酮治疗,研究组接受高频rTMS+利培酮治疗。治疗前后以精神分裂症患者生活质量量表(SQLS)评估两组生活质量,比较两组治疗前后PANSS评分、SQLS评分、不良反应。结果与参照组相比,研究组治疗后PANSS评分、SQLS评分较低,差异有统计学意义(均P<0.05);研究组不良反应发生率[8.11%(3/37)]与参照组[5.41%(2/37)]比较,差异无统计学意义(P>0.05)。结论精神分裂症患者接受高频rTMS联合利培酮治疗能有效改善临床症状,提高生活质量,且安全性高,值得临床推广应用。

作者杨白莎吴磊

机构地区河南科技大学第五附属医院精神科河南科技大学第五附属医院医技科

出处《河南医学研究》 CAS 2020年第8期1399-1401,共3页 Henan Medical Research

关键词精神分裂症高频重复经颅刺激利培酮

分类号 R749.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献3

1赵瑾,张燕,晁阳阳,马骏,杨勇锋,赵晶媛,杜云红,李文强,宋学勤,吕路线.利培酮和奥氮平对首发精神分裂症患者治疗前后认知功能的对比观察[J].中华医学杂志,2016,96(37):2960-2964. 被引量：107
2陈大春,聂鹰,王宁,杨可冰,李艳丽,陈楠,张向阳.利培酮对精神分裂症首次发病患者认知功能及生活技能的影响[J].临床精神医学杂志,2016,26(2):115-117. 被引量：24
3李彬,黎润仪,许锦冰,汤超华,郑广恩.重复经颅磁刺激治疗精神分裂症顽固性幻听的效果及作用机制分析[J].四川医学,2018,39(6):686-689. 被引量：15

二级参考文献36

1Kern RS, Gold J M, Dickinson D, et al. The MCCB impairment pro- file for schizophrenia outpatients : results from the MATRICS psy- chometric and standardization study [ J ]. Schizophr Res, 2011,126 (1/3) :124-131.
2McCleery A, Ventura J, Kern RS, et al. Cognitive functioning in first-episode schizophrenia: MATRICS consensus cognitive battery (MCCB) profile of impairment [ J ]. Schizophrenia Res, 2014,157 (1/3) :33-39.
3Johnson MK, McMahan RP, Robinson BM, et al. The relationshipbetween working memory capacity and broad measures of cognitive ability in healthy adults and people with schizophrenia[ J]. Neuro- psychology, 2013,27 ( 2 ) : 220 -229.
4Mausbach BT, Harvey PD, Goldman SR, et al. Development of a brief scale of everyday functioning in persons with serious mental illness[ J]. Schizophr Bull ,2007,33 (6) : 1364-1372.
5Davidson M, Galderisi S,Weiser M, et al. Cognitive effects of antip- sychotic drugs in first-episode schizophrenia and schizophreniform disorder:a randomized, open-label clinical trial (EUFEST) [ J]. Am J Psychiatry. 2009.166 ( 6 ) :675-682.
6Kahn RS, Keefe RS. Schizophrenia is a cognitive illness : time for a change in tbcus[ Jl. JAMA Psychiatry, 2013,70(10) : 1107- 1112.
7Bowie CR, Reichenberg A, Patterson TL, et al. Determinants of zal-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms [J]. Am J Psychiatry, 2006,163(3) :418-425.
8Green MF, Nuechterlein KH, Kern RS, et al. Functional co- primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study[ J]. Am J Psyehiatry, 2008,165 ( 2 ) : 221-228.
9Kern RS, Nuechterlein KH, Green MF, et al. The MATR1CS Consensus Cognitive Battery, part 2: co-norming and standardization [ J ]. Am J Psychiatry, 2008,165 ( 2 ) : 214-220.
10Nuechterlein KH, Green MF, Kern RS, et al. The MATR1CS Consensus Cognitive Battery, part 1: test selection, reliability, and validity [ J ]. Am J Psychiat3,, 2008, 165 ( 2 ) : 203-213.